Design and delivery of a cryptic PrPC epitope for induction of PrPSc-specific antibody responses

Vaccine

Volumn 28, Issue 4, 2010, Pages 981-988

  Hedlin, Peter D ^a   Cashman, Neil R ^b   Li, Li ^b   Gupta, Jyotsana ^a   Babiuk, Lorne A ^c   Potter, Andrew A ^a   Griebel, Philip ^a   Napper, Scott ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Leukotoxin; Prion; Protein misfolding; Self epitope; Vaccine

Indexed keywords

GLUTAMINYLVALYLTYROSYLTYROSYLARGINYLPROLYLVALYLASPARTYLGLUTAMINYLTYROSYLSERYLASPARAGINYLGLUTAMINYLASPARAGINE; IMMUNOGLOBULIN G ANTIBODY; LEUKOTOXIN; PRION PROTEIN; PRION PROTEIN ANTIBODY; TYROSYLTYROSYLARGININE; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG TARGETING; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; NONHUMAN; NOSE SECRETION; PRIORITY JOURNAL; SHEEP;

ANIMALS; ANTIBODIES; BLOOD; CARRIER PROTEINS; CEREBROSPINAL FLUID; EPITOPES; EXOTOXINS; FEMALE; IMMUNOGLOBULIN G; MALE; MUCOUS MEMBRANE; PRION DISEASES; PRPC PROTEINS; PRPSC PROTEINS; SHEEP; SHEEP DISEASES;

EID: 73949090554     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.134     Document Type: Article

References (33)

1. Silveira J.R., Caughey B., and Baron G.S. Prion protein and the molecular features of transmissible spongiform encephalopathy agents. Curr Top Microbiol Immunol 284 (2004) 1-50
2. Prusiner S.B. Prions. Proc Natl Acad Sci USA 95 November (23) (1998) 13363-13383
3. Geschwind M.D. Clinical trials for prion disease: difficult challenges, but hope for the future. Lancet Neurol 8 April (4) (2009) 304-306
4. Smith P.G., and Bradley R. Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull 66 (2003) 185-198
5. Belay E.D., Maddox R.A., Williams E.S., Miller M.W., Gambetti P., and Schonberger L.B. Chronic wasting disease and potential transmission to humans. Emerg Infect Dis 10 June (6) (2004) 977-984
6. Belay E.D., Gambetti P., Schonberger L.B., Parchi P., Lyon D.R., Capellari S., et al. Creutzfeldt-Jakob disease in unusually young patients who consumed venison. Arch Neurol 58 (2001) 1673-1678
7. Conner M.M., Ebinger M.R., Blanchong J.A., and Cross P.C. Infectious disease in cervids of North America. Ann N Y Acad Sci 1134 (2008) 146-172
8. Hamir A.N., Kunkle M.J.M., Greenlee J.J., and Richt J.A. Experimental second passage of chronic wasting disease (CWD(mule deer)) agent to cattle. J Comp Pathol 134 (2006) 63-69
9. Hamir A.N., Miller J.M., Kunkle R.A., Hall S.M., and Richt J.A. Susceptibility of cattle to first passage intracerebral inoculation with chronic wasting disease agent from white-tailed deer. Vet Pathol 44 (2007) 487-493
10. Enari M., Flechsig E., and Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci USA 98 16 (2001) 9295-9299
11. Peretz D., and Williamson R.A. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412 6848 (2001) 739-743
12. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422 March (6927) (2003) 80-83
13. Goni F., Prelli F., Schreiber F., Scholtzova H., Chung E., Kascsak R., et al. High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 153 May (3) (2008) 679-686
14. Heppner F.L., and Aguzzi A. Recent developments in prion immunotherapy. Curr Opin Immunol 16 October (5) (2004) 594-598
15. Cashman N.R., and Caughey B. Prion diseases-close to effective therapy?. Nat Rev Drug Discov 3 October (10) (2004) 874-884
16. Pilon J., Loiacono C., Okeson D., Lund S., Vercauteren K., Rhyan J., et al. Anti-prion activity generated by a novel vaccine formulation. Neurosci Lett 429 December (2-3) (2007) 161-164
17. Solforosi L., Criado J.R., McGavern D.B., Wirz S., Sanchez-Alavez M., Sugama S., et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303 March (5663) (2004) 1514-1516
18. Mouillet-Richard S., Ermonval M., Chebassier C., Laplanche J.L., Lehmann S., Launay J.M., et al. Signal transduction through prion protein. Science 289 September (5486) (2000) 1925-1928
19. Hooper N.M., and Turner A.J. A new take on prions: preventing Alzheimer's disease. Trends Biochem Sci 33 April (4) (2008) 151-155
20. Paramithiotis E., Pinard M., Lawton T., LaBoissiere S., Leathers V.L., Zou W.Q., et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 9 July (7) (2003) 893-899
21. Zou W.Q., and Cashman N.R. Acidic pH and detergents enhance in vitro conversion of human brain PrPC to a PrPSc-like form. J Biol Chem 277 November (46) (2002) 43942-43947
22. Li L., Guest W., Huang A., Plotkin S.S., and Cashman N.R. Immunological mimicry of PrPC-PrPSc interactions: antibody-induced PrP misfolding. Protein Eng Des Sel July (2009) 523-529
23. Manns J., Barker C., and Attah-Poku S. The design, production, purification, and testing of a chimeric antigen protein to be used as an immunosterilant in domestic animals. Can J Chem 75 (1997) 829-833
24. Robbins S.C., Jelinski M.D., and Stotish R.L. Assessment of the immunological and biological efficacy of two different doses of a recombinant GnRH vaccine in domestic male and female cats (Felis catus). J Reprod Immunol 64 December (1-2) (2004) 107-119
25. Harland R.J., Potter A.A., van Drunen-Littel-van den Hurk S., Van Donkersgoed J., Parker M.D., Zamb T.J., et al. The effect of subunit or modified live bovine herpesvirus-1 vaccines on the efficacy of a recombinant Pasteurella haemolytica vaccine for the prevention of respiratory disease in feedlot calves. Can Vet J 33 November (11) (1992) 734-741
26. Raggo C., Habermehl M., Babiuk L.A., and Griebel P. The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-gamma. J Gen Virol 81 November (Pt 11) (2000) 2665-2673
27. Potter AA, Manns JG. University of Saskatchewan Assignee. GNRH-Leukotoxin Chimeras. US Patent 5,837,268; 1998.
28. Qi Y., Zhang B.Q., Shen Z., and Chen Y.H. Candidate vaccine focused on a classical Swine Fever virus epitope induced antibodies with neutralizing activity. Viral Immunol 22 June (3) (2009) 205-213
29. Heggebo R., Press C.M., Gunnes G., Ulvund M.J., Tranulis M.A., and Lsverk T. Detection of PrPSc in lymphoid tissues of lambs experimentally exposed to the scrapie agent. J Comp Pathol 128 February-April (2-3) (2003) 172-181
30. Poduslo J.F., Curran G.L., Wengenack T.M., Malester B., and Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8 August (4) (2001) 555-567
31. Poduslo J.F., Ramakrishnan M., Holasek S.S., Ramirez-Alvarado M., Kandimalla K.K., Gilles E.J., et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 102 July (2) (2007) 420-433
32. Caughey B., and Raymond G.J. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 266 September (27) (1991) 18217-18223
33. Borchelt D.R., Scott M., Taraboulos A., Stahl N., and Prusiner S.B. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 110 March (3) (1990) 743-752